2012
Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome
Boden WE, Lansky A, Angiolillo DJ. Refining the Role of Antiplatelet Therapy in Medically Managed Patients With Acute Coronary Syndrome. The American Journal Of Cardiology 2012, 111: 439-444. PMID: 23168289, DOI: 10.1016/j.amjcard.2012.10.018.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeDual antiplatelet therapyAntiplatelet therapyCoronary syndromeHigh-risk percutaneous coronary interventionUnmet needPotent platelet inhibitionChronic kidney diseaseComplex coronary anatomyFirst-line therapyHigh-risk patientsLow-risk patientsPercutaneous coronary interventionSubgroup of patientsPrevious revascularizationPharmacologic managementCoronary interventionRisk patientsDiabetes mellitusPlatelet inhibitionSuch patientsCoronary anatomyKidney diseaseTherapeutic optionsTreatment options
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban